Program
lifitegrast
Also written as “Lifitegrast”, “Xiidra®” and “Lifitegrast/Perfluorohexyloctane Fixed Dose Combination”.
Its studies are mostly in Dry Eye Syndromes · Keratoconjunctivitis Sicca · Conjunctivitis, Allergic, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 60 open or running | phase 3since Aug 17, 2011 | Apr 15, 2009 | none ahead |
| Hoffmann-La Roche | 10 open or running | phase 4since Jun 16, 2025 | Jun 16, 2025 | none ahead |
| Qilu Pharmaceutical | 10 open or running | phase 1since Jun 18, 2025 | Jun 18, 2025 | none ahead |
| Research Insight | 10 open or running | phase 4since Dec 9, 2020 | Dec 9, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 15, 2009First study: phase 2 study in Conjunctivitis, AllergicNew to TakedaTakeda · NCT00882687 · 60 enrolled · United States
- Jun 20, 2009Phase 2 study in Dry Eye SyndromesTakeda · NCT00926185 · 230 enrolled · United States
- Aug 17, 2011Phase 3 study in Keratoconjunctivitis SiccaTakeda · NCT01421498 · 588 enrolled · United States
- Jul 5, 2012Phase 3 study in Dry Eye SyndromesTakeda · NCT01636206 · 332 enrolled · United States
- Dec 3, 2012Phase 3 study in Dry Eye SyndromesTakeda · NCT01743729 · 720 enrolled · United States
- Oct 30, 2014Phase 3 study in Dry Eye SyndromesTakeda · NCT02284516 · 711 enrolled · United States
- Dec 9, 2020Research Insight's first study: phase 4 study in Dry Eye SyndromesNew to Research InsightResearch Insight · NCT04669561 · 100 enrolled · United States
- Jun 16, 2025Hoffmann-La Roche's first study: phase 4 study in Dry Eye SyndromesNew to Hoffmann-La RocheHoffmann-La Roche · NCT07025811 · 378 enrolled · United States
- Jun 18, 2025Qilu Pharmaceutical's first study: phase 1 study in Dry Eye SyndromesNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT07040826 · 24 enrolled · China
TargetBeta
“A tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 (LFA-1) antagonist, that can be used as an ophthalmic solution for the treatment of dry eye disease (DED; keratoconjunctivitis sicca; dry eye syndrome)”NCIt, by rule
“Integrin alpha-L/beta-2 (LFA-1) antagonist”ChEMBL 37, by rule
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07040826Dry Eye Syndromes · China | 1 | Completed | Qilu Pharmaceutical | Dec 19, 2022 | 24 |
| NCT07025811Dry Eye Syndromes · United States | 4 | Completed | Hoffmann-La Roche | Jul 16, 2026 | 378 |
| NCT04669561Dry Eye Syndromes · United States | 4 | Completed | Research Insight | Aug 31, 2021 | 100 |
| NCT02284516Dry Eye Syndromes · United States | 3 | Completed | Takeda | Oct 5, 2015 | 711 |
| NCT01743729Dry Eye Syndromes · United States | 3 | Completed | Takeda | Oct 1, 2013 | 720 |
| NCT01636206Dry Eye Syndromes · United States | 3 | Completed | Takeda | Mar 3, 2014 | 332 |
| NCT01421498Keratoconjunctivitis Sicca · United States | 3 | Completed | Takeda | Apr 28, 2012 | 588 |
| NCT00926185Dry Eye Syndromes · United States | 2 | Completed | Takeda | Feb 18, 2010 | 230 |
| NCT00882687Conjunctivitis, Allergic · United States | 2 | Completed | Takeda | May 10, 2009 | 60 |
How it is read
Names in the registry
- “Lifitegrast”, 7 entries
- “Xiidra®”, 1 entry
- “Lifitegrast/Perfluorohexyloctane Fixed Dose Combination”, 1 entry
- “Lifitegrast/perfluorohexyloctane (PFHO)”, 1 entry
- “Xiidra”, 1 entry
Conditions, from the studies’ own filings
- Dry Eye Syndromes, 9 studies
- Keratoconjunctivitis Sicca, 1 study
- Conjunctivitis, Allergic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.